Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rapid urine test could speed up UTI diagnosis and antibiotic selection

NCT ID NCT07784829

Diagnosis Sponsor: Medstar Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial is testing a new rapid urine test called Jiddu that aims to quickly identify urinary tract infections (UTIs) and determine which antibiotics will work best. The study involves 100 adults with neurogenic bladder who use catheters and suspect they have a UTI. Participants provide urine samples that are analyzed using both standard methods and the experimental Jiddu device. The goal is to see if Jiddu can accurately detect UTIs and guide antibiotic treatment, potentially leading to faster and more targeted therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Jiddu platform, a microfluidic device that rapidly tests urine for bacteria and antibiotic susceptibility
What this could lead to
If successful, this could provide a faster, more accurate way to diagnose UTIs and choose effective antibiotics, reducing the need for broad-spectrum drugs and improving care for catheter users.
What could go wrong
This is an early-stage diagnostic trial with a relatively small sample size. The test's accuracy and clinical utility are not yet proven, and it may not outperform standard culture methods in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age≥18 years; * patient-reported diagnosis of neurogenic bladder; * using urethral or suprapubic catheterization for bladder management; * presenting for suspected symptomatic UTI; and * lives in community or nursing home. Exclusion Criteria: * antibiotic treatment for suspected UTI within past 4 weeks - including as a participant in this study; * bladder-instilled antibiotic within the past 2 weeks; * psychologic or psychiatric conditions influencing the ability to follow instructions; and * participation in another study in which results would be confounded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lower urinary tract disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease urinary bladder disorder Urinary Bladder, Neurogenic urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lower urinary tract disorder Neurogenic bladder disorder Urinary tract infection (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MedStar National Rehabilitation Hospital

    Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.